Advanced Biologics merges with Isto Biologics, expanding regenerative therapy portfolios

TAGS

Advanced Biologics, the California-based biologic solutions innovator, has today publicized its merger with the renowned Isto Biologics, recognized globally for its leading-edge regenerative and autologous therapies. This pivotal merger is set to integrate the proprietary offerings of Advanced Biologics into Isto’s already expansive allograft portfolio under the Influx lineup.

Merger Overview: Bringing Together Expertise and Innovation

As Amit Govil, President of Advanced Biologics, mentioned, “We are thrilled for our entire Advanced Biologics/Biologica team to join forces with Isto Biologics. This merger brings together the clinical, commercial, and research-driven expertise of both companies and a shared commitment to help patients heal faster.”

See also  Trimble to acquire logistics software company Transporeon for €1.9bn

Historically, Advanced Biologics and Isto Biologics have collaborated since 2020, a relationship fostered by the innovative Isto’s Integrative Bone Matrix, SPARC. Originating from Advanced Biologics’ distinctive tissue processing method, this inductive bone matrix – also known as SPARC – has been recognized for its heightened levels of osteoinductive, chemotactic, angiogenic, and proliferative growth elements.

See also  Microsoft posts $56.5bn revenue for Q3 2023, up by 13% YoY

Promising Future for Both Entities Post-Merger

The merger capitalizes on the joint strengths of both firms, uniquely positioning them to accelerate patient healing and furnishing an enriched product suite for their combined clientele. Reflecting on the companies’ collaborative history, Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners (TSCP), said, “Over the past four years, our collaboration with Advanced Biologics has been impressive… paving a path forward for continued growth and patient healing.”

See also  Coca-Cola signs cloud and digital transformation deal with Microsoft

Echoing similar sentiments, Don Brown, CEO of Isto Biologics, expressed, “With this merger, our combined team is now elevated with greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This